METROPOLISNSENovember 04, 2025

Metropolis Healthcare Limited

5,488words
1turns
0analyst exchanges
0executives
Key numbers — 40 extracted
11%
imes and turn their anxiety into assurance 43+ years of credible experience 221 Clinical Labs 11% CAGR revenue growth in last 7 years 4,000+ Tests & Profiles 35 ISO:15189 Accredited Labs (31 i
rs 4,000
ance 43+ years of credible experience 221 Clinical Labs 11% CAGR revenue growth in last 7 years 4,000+ Tests & Profiles 35 ISO:15189 Accredited Labs (31 in India / 4 in Kenya) 2 CAP Accredited Lab (
INR 429
Ambika Pathology, Kolhapur – 18 September 2025 Q2 & H1FY26 Key Financials – MHL Group Revenue INR 429 Cr +23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA
23%
ology, Kolhapur – 18 September 2025 Q2 & H1FY26 Key Financials – MHL Group Revenue INR 429 Cr +23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 19
INR 815
8 September 2025 Q2 & H1FY26 Key Financials – MHL Group Revenue INR 429 Cr +23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 198 Cr +17% YoY PAT bu
INR 109
ncials – MHL Group Revenue INR 429 Cr +23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 198 Cr +17% YoY PAT business & acquisitions • Revenue growth
19%
Group Revenue INR 429 Cr +23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 198 Cr +17% YoY PAT business & acquisitions • Revenue growth fueled
INR 198
+23% YoY Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 198 Cr +17% YoY PAT business & acquisitions • Revenue growth fueled by organic INR 53 Cr +13% Yo
17%
Revenue INR 815 Cr +23% YoY Q2FY26 EBITDA INR 109 Cr +19% YoY H1FY26 EBITDA INR 198 Cr +17% YoY PAT business & acquisitions • Revenue growth fueled by organic INR 53 Cr +13% YoY PAT
INR 53
EBITDA INR 198 Cr +17% YoY PAT business & acquisitions • Revenue growth fueled by organic INR 53 Cr +13% YoY PAT INR 98 Cr +16% YoY • Q2FY26, EBITDA margin at group level stood at 25.4% com
13%
R 198 Cr +17% YoY PAT business & acquisitions • Revenue growth fueled by organic INR 53 Cr +13% YoY PAT INR 98 Cr +16% YoY • Q2FY26, EBITDA margin at group level stood at 25.4% compared to
INR 98
YoY PAT business & acquisitions • Revenue growth fueled by organic INR 53 Cr +13% YoY PAT INR 98 Cr +16% YoY • Q2FY26, EBITDA margin at group level stood at 25.4% compared to 23.1% in Q1FY26
Speaking time
Investor Relations Advisors
1
Opening remarks
Investor Relations Advisors
http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. CIN – L73100MH2000PLC192798 Mr. Kamlesh Kulkarni Email Id – secretarial@metropolisindia.com www.metropolisindia.com Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff shogun.jain@sgapl.net / sagar.shroff@sgapl.net +91 77383 77756 / +91 98205 19303 www.sgapl.net 29
← All transcriptsMETROPOLIS stock page →